IOL Chemicals and Pharmaceuticals Limited — Investor Meet, 13-08-2025: Analysts/Institutional Investor Meet/Con. Call Updates

IOL Chemicals and Pharmaceuticals reported robust Q1 FY26 results: Revenue grew 9.8% YoY to Rs. 552 crore, EBITDA increased 19.5% to Rs. 69.5 crore (12.4% margin), and PAT rose 14.4% to Rs. 34 crore. The company aims to balance Ibuprofen and non-Ibuprofen API portfolios 50-50, targeting 40% export revenue within two years from current 25%. New Paracetamol plant utilization is projected to reach 60% by Q3 FY26. Management expects 10% revenue growth and 14-15% blended EBITDA margin for FY26, driven by capacity utilization and backward integration. The outlook remains confident on strategic execution.